Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000360670

Medchemexpress LLC Dabrafenib Mesylate | 1195768-06-9 | 99.9% | 615.67 | 100 MG
SDP

Catalog No. 5000360670
Encompass_Preferred

Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively. It is intended for research use only.

  • Inhibits more than 90% of cell growth in NRAS mutant clones when combined with GSK1120212.
  • Reduces S6P phosphorylation in A375 cells.
  • Suppresses polyp-mediated vascular barrier permeability, inflammatory biomarker upregulation, leukocyte adhesion/migration, and activation/production of NF-κB, TNF-α, and IL-6.
  • Inhibits HMGB1 release and downregulates HMGB1-dependent inflammatory responses by enhancing cell adhesion molecule (CAMs) expressions in human endothelial cells.
  • In vivo studies showed that dabrafenib-treated females had mostly immature reproductive tracts with no evidence of ovulation, but keratinized and histologically open vaginas.

Catalog No. 50-003-60670 Supplier Medchemexpress LLC Supplier No. HY14660A100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively. It is intended for research use only.

  • Inhibits more than 90% of cell growth in NRAS mutant clones when combined with GSK1120212.
  • Reduces S6P phosphorylation in A375 cells.
  • Suppresses polyp-mediated vascular barrier permeability, inflammatory biomarker upregulation, leukocyte adhesion/migration, and activation/production of NF-κB, TNF-α, and IL-6.
  • Inhibits HMGB1 release and downregulates HMGB1-dependent inflammatory responses by enhancing cell adhesion molecule (CAMs) expressions in human endothelial cells.
  • In vivo studies showed that dabrafenib-treated females had mostly immature reproductive tracts with no evidence of ovulation, but keratinized and histologically open vaginas.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.